INTENSITY THERAPEUTICS INC (INTS) Stock Price, Forecast & Analysis
NASDAQ:INTS • US45828J1034
INTS Key Statistics, Chart & Performance
The current stock price of INTS is 5.86 USD. In the past month the price decreased by -42.02%. In the past year, price decreased by -89.49%.
INTS Technical Analysis
INTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INTS. No worries on liquidiy or solvency for INTS as it has an excellent financial health rating, but there are worries on the profitability.
INTS Financial Highlights
Over the last trailing twelve months INTS reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 41.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.44% | ||
| ROE | -162.5% | ||
| Debt/Equity | 0 |
INTS Forecast & Estimates
12 analysts have analysed INTS and the average price target is 2.98 USD. This implies a price decrease of -49.23% is expected in the next year compared to the current price of 5.86.
INTS Ownership
INTS Latest News, Press Relases and Analysis
INTS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INTS
Company Profile
Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Company Info
INTENSITY THERAPEUTICS INC
1 Enterprise Drive, Suite 430
Shelton CONNECTICUT US
Employees: 5
Phone: 12032217381
INTENSITY THERAPEUTICS INC / INTS FAQ
What does INTS do?
Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Can you provide the latest stock price for INTENSITY THERAPEUTICS INC?
The current stock price of INTS is 5.86 USD. The price decreased by -10.12% in the last trading session.
Does INTENSITY THERAPEUTICS INC pay dividends?
INTS does not pay a dividend.
How is the ChartMill rating for INTENSITY THERAPEUTICS INC?
INTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is INTENSITY THERAPEUTICS INC (INTS) stock traded?
INTS stock is listed on the Nasdaq exchange.
Should I buy INTS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INTS.
Can you provide the market cap for INTENSITY THERAPEUTICS INC?
INTENSITY THERAPEUTICS INC (INTS) has a market capitalization of 351.95M USD. This makes INTS a Small Cap stock.